Lumito participated with a booth of our own at the Digital Pathology & AI Congress in London in early December. The congress was attended by over 440 delegates and was held at a conference hotel at Heathrow. The delegates, primarily from Western Europe, were specifically interested in the digitalization of pathology with both research and clinical focus. The majority of the visitors to the stand were knowledgeable about Lumito's technology, actively seeking out the Lumito stand, and wanting to know more about the technology and its possibilities.
"Your technology adds a new dimension that does not exist today, digitalization combined with immunohistochemistry and specific nanoparticles allows a completely free channel that does not hide anything in the tissue interface when imaging" was one of the comments.
“The value-added benefits offered by Lumito's technology were made clear to more visitors as their knowledge increased. It became very clear that we have something different from today's technology and that we have a position among already established companies. Our technology enables an extra invisible signal within traditional immunohistochemical (IHC) workflow – something that is completely unique and thereby interesting for potential end-customers and partners, comments Mattias Lundin, Lumito's CEO.
The company is now in the process of following up, communicating and taking the next steps with both new and previous contacts.
For further information, please contact:
Lumito's CEO, Mattias Lundin
e-mail: ml@lumito.se
Ph: +46 768 684 509
Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalized healthcare. The technology enables higher contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has chosen to focus primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off from a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en
The share is traded on NGM Nordic SME, under the name LUMITO and Mentor is Mangold Fondkommission, phone: +46 8503 015 50.
